Pediatrix Medical Group, Inc.
MDNYSEHealthcare● Active
$22.61
+$0.24(+1.07%)
Market Cap$1.9B
P/E Ratio—
52W High$24.99
52W Low$11.84
Pediatrix Medical Group, Inc. (MD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MD · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
$0.44
Est. $0.37 · +18.9%
Revenue
$0.48B
Est. $0.47B · +2.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
MD reports quarterly as a NYSE-listed Medical - Care Facilities company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $7.60B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$7.60B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $0.57 | — | — | — | $0.48B | — |
| ▲ Q2 FY2026 | May 5, 2026 | $0.37 | $0.44 | +18.9% | $0.48B | $0.47B | +2.2% |
| ▼ Q1 FY2026 | Feb 19, 2026 | $0.53 | $0.50 | -5.7% | $0.49B | $0.49B | +1.6% |
| ▲ Q4 FY2025 | Nov 3, 2025 | $0.46 | $0.67 | +45.6% | $0.49B | $0.49B | +1.4% |
| ▲ Q3 FY2025 | Aug 5, 2025 | $0.42 | $0.53 | +26.2% | $0.47B | $0.47B | -1.0% |
| ▲ Q2 FY2025 | May 6, 2025 | $0.25 | $0.33 | +32.0% | $0.46B | $0.46B | -0.3% |
| ▲ Q1 FY2025 | Feb 20, 2025 | $0.37 | $0.51 | +37.8% | $0.50B | $0.47B | +6.2% |
| ▲ Q4 FY2024 | Nov 1, 2024 | $0.37 | $0.44 | +18.9% | $0.51B | $0.49B | +5.0% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$0.57
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
$0.44
EPS Est.
$0.37
EPS Surpr.
+18.9%
Revenue
$0.48B
Q1 FY2026
Feb 19, 2026Miss
EPS Actual
$0.50
EPS Est.
$0.53
EPS Surpr.
-5.7%
Revenue
$0.49B
Q4 FY2025
Nov 3, 2025Beat
EPS Actual
$0.67
EPS Est.
$0.46
EPS Surpr.
+45.6%
Revenue
$0.49B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
$0.53
EPS Est.
$0.42
EPS Surpr.
+26.2%
Revenue
$0.47B
Q2 FY2025
May 6, 2025Beat
EPS Actual
$0.33
EPS Est.
$0.25
EPS Surpr.
+32.0%
Revenue
$0.46B
Q1 FY2025
Feb 20, 2025Beat
EPS Actual
$0.51
EPS Est.
$0.37
EPS Surpr.
+37.8%
Revenue
$0.50B
Q4 FY2024
Nov 1, 2024Beat
EPS Actual
$0.44
EPS Est.
$0.37
EPS Surpr.
+18.9%
Revenue
$0.51B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.59 | $0.60 | $0.61 | 2 |
| Q3 FY2028 | $0.71 | $0.73 | $0.74 | 2 |
| Q2 FY2028 | $0.60 | $0.61 | $0.62 | 2 |
| Q1 FY2028 | $0.45 | $0.46 | $0.47 | 2 |
| Q4 FY2027 | $0.59 | $0.60 | $0.61 | 1 |
| Q3 FY2027 | $0.64 | $0.65 | $0.66 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.5B | $0.5B | $0.5B | 1 |
| Q3 FY2028 | $0.5B | $0.5B | $0.5B | 1 |
| Q2 FY2028 | $0.5B | $0.5B | $0.5B | 1 |
| Q1 FY2028 | $0.5B | $0.5B | $0.5B | 1 |
| Q4 FY2027 | $0.5B | $0.5B | $0.5B | 2 |
| Q3 FY2027 | $0.5B | $0.5B | $0.5B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +18.9% | $22.41 | $20.83 | -7.05% |
| ▼ Q1 FY2026 | Feb 19, 2026 | -5.7% | $21.97 | $19.30 | -12.15% |
| ▲ Q4 FY2025 | Nov 3, 2025 | +45.6% | $16.97 | $21.08 | +24.22% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +26.2% | $12.30 | $12.92 | +5.04% |
| ▲ Q2 FY2025 | May 6, 2025 | +32.0% | $12.95 | $14.48 | +11.81% |
| ▲ Q1 FY2025 | Feb 20, 2025 | +37.8% | $14.11 | $17.23 | +22.11% |
| ▲ Q4 FY2024 | Nov 1, 2024 | +18.9% | $12.32 | $15.21 | +23.46% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +9.7% | $7.62 | $8.97 | +17.72% |
Q2 FY2026-7.05%
Report Date
May 5, 2026
EPS Beat/Miss
+18.9%
Price Before
$22.41
Price After
$20.83
Q1 FY2026-12.15%
Report Date
Feb 19, 2026
EPS Beat/Miss
-5.7%
Price Before
$21.97
Price After
$19.30
Q4 FY2025+24.22%
Report Date
Nov 3, 2025
EPS Beat/Miss
+45.6%
Price Before
$16.97
Price After
$21.08
Q3 FY2025+5.04%
Report Date
Aug 5, 2025
EPS Beat/Miss
+26.2%
Price Before
$12.30
Price After
$12.92
Q2 FY2025+11.81%
Report Date
May 6, 2025
EPS Beat/Miss
+32.0%
Price Before
$12.95
Price After
$14.48
Q1 FY2025+22.11%
Report Date
Feb 20, 2025
EPS Beat/Miss
+37.8%
Price Before
$14.11
Price After
$17.23
Q4 FY2024+23.46%
Report Date
Nov 1, 2024
EPS Beat/Miss
+18.9%
Price Before
$12.32
Price After
$15.21
Q3 FY2024+17.72%
Report Date
Aug 6, 2024
EPS Beat/Miss
+9.7%
Price Before
$7.62
Price After
$8.97
Avg Beat Reaction+13.90%
Avg Miss Reaction-12.15%
Beat Rate7 / 8 quarters
Largest Move+24.22% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MD ends December
Pediatrix Medical Group, Inc. (MD) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $0.44 — beating the analyst consensus of $0.37 by +18.9%. The next MD earnings date is expected around September 1, 2026.
Each quarter, investors track MD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MD earnings · 5 questionsPediatrix Medical Group, Inc.'s next earnings report is expected around September 1, 2026. MD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MD historically reports after market close (AMC).
MD earnings datewhen is MD earningsMD next earnings datewhen does MD report earningsMD earnings calendar
▸ Source: FMP · Pediatrix Medical Group, Inc. SEC filings · US GAAP · Pediatrix Medical Group, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026